Adibhatla, R. M., Hatcher JF, and Dempsey RJ. Effects of citicholine on phospholipid and glutathione levels in transient cerebral ischemia. Stroke ;32(10):-.
Goto Witspower to know more.
Agnoli A, Fioravanti M, and Lechner H. Efficacy of CDP-Choline in chronic cerebral vascular diseases (CCVD). In: Zappia V, Kennedy EP, Nilsson BI, and Galletti PV. Novel Biochemical, Pharmacological, and Clinical Aspects of Cytidinediphosphocholine. New York: Elsevier Science;.
Aizawa, K., Kanai, T., Saikawa, Y., Takabayashi, T., Kawano, Y., Miyazawa, N., and Yamamoto, T. A novel approach to the prevention of postoperative delirium in the elderly after gastrointestinal surgery. Surg.Today. ;32(4):310-314. View abstract.
Alvarez, X. A., Laredo, M., Corzo, D., Fernandez-Novoa, L., Mouzo, R., Perea, J. E., Daniele, D., and Cacabelos, R. Citicoline improves memory performance in elderly subjects. Methods.Find.Exp.Clin.Pharmacol. ;19(3):201-210. View abstract.
Alvarez, X. A., Mouzo, R., Pichel, V., Perez, P., Laredo, M., Fernandez-Novoa, L., Corzo, L., Zas, R., Alcaraz, M., Secades, J. J., Lozano, R., and Cacabelos, R. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods.Find.Exp.Clin.Pharmacol. ;21(9):633-644. View abstract.
Angeli G. Clinical study on Asonic (provisional name) [Sperimentazione clinica sul prodotto denominato provvisoriamente Asonic]. Rivista di Neuropsichiatria e Scienze Affini ;31:13-24.
Arranz, J. and Ganoza, C. Treatment of chronic dyskinesia with CDP-choline. Arzneimittelforschung. ;33(7A):-. View abstract.
Ataus S, Onal M, Zulkuf M, and et al. The effects of citicholine and lamotrigine alone and in combination following permanent middle cerebral artery occlusion in rats. International Journal of Neuroscience ;114(2):183-196.
Babb, S. M., Wald, L. L., Cohen, B. M., Villafuerte, R. A., Gruber, S. A., Yurgelun-Todd, D. A., and Renshaw, P. F. Chronic citicoline increases phosphodiesters in the brains of healthy older subjects: an in vivo phosphorus magnetic resonance spectroscopy study. Psychopharmacology.(Berl.) ;161(3):248-254. View abstract.
Barbagallo-Sangiorgi G, Ceruso D, Cuzzupoli MF, and et al. Double-blind, multicenter study on CDP-choline in patients with primary senile mental deterioration [Studio multicentrico in doppio cieco con Citicolina nel deterioramento mentale senile primitivo]. Invecchiamento Cerebrale e Cerebrovasculopatie Croniche ;
Berggren, D., Gustafson, Y., Eriksson, B., Bucht, G., Hansson, L. I., Reiz, S., and Winblad, B. Postoperative confusion after anesthesia in elderly patients with femoral neck fractures. Anesth.Analg. ;66(6):497-504. View abstract.
Bettini, R. and Gorini, M. [Reaction times during citicoline treatment]. Clin.Ter. ;153(4):247-250. View abstract.
Bonavita E, Chioma V, Dall'Oca P, and et al. Double-blind study on CDP-choline activity in primitive mild cognitive deterioration cases [Studio in doppio cieco sull'azione della citicolina nel cervello senile]. Minerva Psichiatrica ;24:53-62.
Bonavita, E. [Neuropsychological study of the senile brain during and after single and combined treatment with deanol and citicoline]. Clin.Ter. 6-15-;117(5):387-398. View abstract.
Brown, E. S., Gorman, A. R., and Hynan, L. S. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin.Psychopharmacol. ;27(5):498-502. View abstract.
Campos, E. C., Schiavi, C., Benedetti, P., Bolzani, R., and Porciatti, V. Effect of citicoline on visual acuity in amblyopia: preliminary results. Graefes.Arch Clin.Exp.Ophthalmol. ;233(5):307-312. View abstract.
Capurso A, Capurso S, Panza F, and et al. Efficacy of cytidine diphosphate choline in patients affected by chronic cerebrovascular disease. Clinical Drug Investigation ;12(1):26-38.
Centrone, G., Ragno, G., and Calicchio, G. [Use of citicoline in high dosages in acute cerebrovascular disease]. Minerva Med 3-17-;77(11):371-373. View abstract.
Clark, W. M., Warach, S. J., Pettigrew, L. C., Gammans, R. E., and Sabounjian, L. A. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group. Neurology. ;49(3):671-678. View abstract.
Clark, W. M., Wechsler, L. R., Sabounjian, L. A., and Schwiderski, U. E. A phase III randomized efficacy trial of mg citicoline in acute ischemic stroke patients. Neurology. 11-13-;57(9):-. View abstract.
Clark, W. M., Williams, B. J., Selzer, K. A., Zweifler, R. M., Sabounjian, L. A., and Gammans, R. E. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke. ;30(12):-. View abstract.
Cubells, J. M. and Hernando, C. Clinical trial on the use of cytidine diphosphate choline in Parkinson's disease. Clin.Ther ;10(6):664-671. View abstract.
D'Orlando, K. J. and Sandage, B. W., Jr. Citicoline (CDP-choline): mechanisms of action and effects in ischemic brain injury. Neurol.Res ;17(4):281-284. View abstract.
Di, Trapani G. and Fioravanti, M. [Citicoline in the treatment of cognitive and behavioral disorders in pathologic senile decline]. Clin.Ter. 6-30-;137(6):403-413. View abstract.
Diaz, V., Rodriguez, J., Barrientos, P., Serra, M., Salinas, H., Toledo, C., Kunze, S., Varas, V., Santelices, E., Cabrera, C., Farias, J., Gallardo, J., Beddings, M. I., Leiva, A., and Cumsille, M. A. [Use of procholinergics in the prevention of postoperative delirium in hip fracture surgery in the elderly. A randomized controlled trial]. Rev.Neurol. 10-16-;33(8):716-719. View abstract.
Dinsdale, J. R., Griffiths, G. K., Castello, J., Maddock, J., Ortiz, J. A., and Aylward, M. CDP-choline: repeated oral dose tolerance studies in adult healthy volunteers. Arzneimittelforschung. ;33(7A):-. View abstract.
Dinsdale, J. R., Griffiths, G. K., Rowlands, C., Castello, J., Ortiz, J. A., Maddock, J., and Aylward, M. Pharmacokinetics of 14C CDP-choline. Arzneimittelforschung. ;33(7A):-. View abstract.
Eberhardt, R., Birbamer, G., Gerstenbrand, F., Rainer, E., and Traegner, H. Citicoline in the treatment of Parkinson's disease. Clin.Ther ;12(6):489-495. View abstract.
Falchi Delitata G, Falchi Delitata N, Casali R, and et al. Intermediate term, double-blind vs. placebo study of CDP-choline in cases with cognitive senile deterioration. Gazzetta Medica Italiana - Archivio Scienze Mediche ;143:789-810.
Fioravanti, M. and Yanagi, M. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database.Syst.Rev. ;(2):CD. View abstract.
Fridman, E. A., Ottaviano, F., Fiol, M., Javelier, A., Perea, J. E., and Ameriso, S. F. [Neuroprotection in acute ischemic stroke. Practicability of guidelines for treatment]. Rev.Neurol. 5-1-;32(9):818-821. View abstract.
Iranmanesh, F. and Vakilian, A. Efficiency of citicoline in increasing muscular strength of patients with nontraumatic cerebral hemorrhage: a double-blind randomized clinical trial. J Stroke.Cerebrovasc.Dis. ;17(3):153-155. View abstract.
Kalisvaart, K. J., de Jonghe, J. F., Bogaards, M. J., Vreeswijk, R., Egberts, T. C., Burger, B. J., Eikelenboom, P., and van Gool, W. A. Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. J Am.Geriatr Soc ;53(10):-. View abstract.
León-Carrión J, Dominguez-Roldán JM, Murillo-Cabezas F, Dominguez-Morales MR, and Munoz-Sanchez MA. The role of citicholine in neuropsychological training after traumatic brain injury. NeuroRehabilitation ;14(1):33-40.
Liptzin B, Laki A, Garb, and et al. Donepezil in the Prevention and Treatment of Post-Surgical Delirium. American Journal of Geriatric Psychiatry ;13:-.
Lozano, Fernandez R. Efficacy and safety of oral CDP-choline. Drug surveillance study in cases. Arzneimittelforschung. ;33(7A):-. View abstract.
Lukas, S. E., Kouri, E. M., Rhee, C., Madrid, A., and Renshaw, P. F. Effects of short-term citicoline treatment on acute cocaine intoxication and cardiovascular effects. Psychopharmacology.(Berl.) ;157(2):163-167. View abstract.
Madariaga Aguirre L. A double-blind evaluation on a group of senile female patients, treated with CDP-choline. Revista de Psiquiatría y Psicología Médica ;13(5):331-342.
Marcantonio, E. R., Flacker, J. M., Wright, R. J., and Resnick, N. M. Reducing delirium after hip fracture: a randomized trial. J Am.Geriatr Soc ;49(5):516-522. View abstract.
Marti Masso, J. F. and Urtasun, M. Citicoline in the treatment of Parkinson's disease. Clin.Ther ;13(2):239-242. View abstract.
Motta L, Fichera G, Tiralosi G, and et al. CDP-choline in the treatment of chronic cerebrovasculopaties [La citicolina nel tratta mento delle cerebrovasculopatie croniche]. Unpublished Lederle (Cyanamid Italia) report. ;
Parisi, V., Coppola, G., Centofanti, M., Oddone, F., Angrisani, A. M., Ziccardi, L., Ricci, B., Quaranta, L., and Manni, G. Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog.Brain.Res ;173:541-554. View abstract.
Parisi, V., Coppola, G., Ziccardi, L., Gallinaro, G., and Falsini, B. Cytidine-5'-diphosphocholine (Citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. Eur.J Neurol. ;15(5):465-474. View abstract.
Parisi, V., Manni, G., Colacino, G., and Bucci, M. G. Cytidine-5'-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology. ;106(6):-. View abstract.
Pecori, Giraldi J., Virno, M., Covelli, G., Grechi, G., and De, Gregorio F. Therapeutic value of citicoline in the treatment of glaucoma (computerized and automated perimetric investigation). Int Ophthalmol. ;13(1-2):109-112. View abstract.
Petkov, V. D., Stancheva, S. L., Tocuschieva, L., and Petkov, V. V. Changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine (experiments on rats). Gen.Pharmacol. ;21(1):71-75. View abstract.
Piccoli, F., Battistini, N., Carbonin, P., Curro, Dossi B., Fiori, L., La, Bella, V, Megna, G., Salvioli, G., and Fioravanti, M. CDP-choline in the treatment of chronic cerebrovasculopathies. Arch Gerontol Geriatr ;18(3):161-168. View abstract.
Radad K, Gille G, Xiaojing J, Durany N, and Rausch W-D. CDP-choline reduces dopaminergic cell loss induced by MPP-super(+) and glutamate in primary mesencephalic cell culture. International Journal of Neuroscience ;117(7):985-998.
Renshaw, P. F., Daniels, S., Lundahl, L. H., Rogers, V., and Lukas, S. E. Short-term treatment with citicoline (CDP-choline) attenuates some measures of craving in cocaine-dependent subjects: a preliminary report. Psychopharmacology.(Berl.) ;142(2):132-138. View abstract.
Rossi, M. and Zanardi, M. [An open study on the clinical efficacy of citicoline in patients with chronic cerebral vasculopathy]. Clin.Ter. ;142(2):141-144. View abstract.
Salvadorini F. Clinical evaluation of CDP-choline (Nicholin): Efficacy as antidepressant treatment. Therapeutic Research ;18(3):513-520.
Secades, J. J. and Lorenzo, J. L. Citicoline: pharmacological and clinical review, update. Methods.Find.Exp.Clin.Pharmacol. ;28 Suppl B:1-56. View abstract.
Secades, J. J., Alvarez-Sabin, J., Rubio, F., Lozano, R., Davalos, A., and Castillo, J. Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc.Dis. ;21(5-6):380-385. View abstract.
Senin U and Fioravanti M. Clinical controlled study vs placebo of CDPcholine in a large group of aged patients with cerebrovascular dementia. Wyeth, Italy ;
Serra, F., Diaspri, G. P., Gasbarrini, A., Giancane, S., Rimondi, A., Tame, M. R., Sakellaridis, E., Bernardi, M., and Gasbarrini, G. [Effect of CDP-choline on senile mental deterioration. Multicenter experience on 237 cases]. Minerva Med. ;81(6):465-470. View abstract.
Siddiqi, N., Stockdale, R., Britton, A. M., and Holmes, J. Interventions for preventing delirium in hospitalised patients. Cochrane Database.Syst.Rev. ;(2):CD. View abstract.
Sinforiani E, Trucco M, Pacchetti C, and et al. Assessment of CDPcholine effects in patients with chronic cerebrovascular disease [Valutazione degli effetti della citicolina nella malattia cerebro-vascolare cronica]. Minerva Medica ;77(51):57.
Sinforiani, E., Trucco, M., Pacchetti, C., and Gualtieri, S. [Evaluation of the effects of citicoline in chronic cerebrovascular diseases]. Minerva Med 1-14-;77(1-2):51-57. View abstract.
Stramba-Badiale, M. and Scillieri, E. [Citicoline activity in senile mental decay]. Minerva Med 4-7-;74(14-15):819-821. View abstract.
Suryani L, Adnjana T, and Jensen G. Citicholine treatment of memory deficits in elderly people. International Journal of Geriatric Psychiatry ;3(3):235-236.
Tanaka, Y., Minematsu, K., Hirano, T., Hayashida, K., and Yamaguchi, T. [Effects of CDP-choline on dynamic changes in LCBF and cognitive function in demented subjects--an H2 15O-PET study]. Rinsho.Shinkeigaku. ;34(9):877-881. View abstract.
Trovarelli, G., de Medio, G. E., Dorman, R. V., Piccinin, G. L., Horrocks, L. A., and Porcellati, G. Effect of cytidine diphosphate choline (CDP-choline) on ischemia-induced alterations of brain lipid in the gerbil. Neurochem.Res ;6(8):821-833. View abstract.
Virno, M., Pecori-Giraldi, J., Liguori, A., and De, Gregorio F. The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). Acta Ophthalmol.Scand.Suppl ;(232):56-57. View abstract.
Warach, S., Pettigrew, L. C., Dashe, J. F., Pullicino, P., Lefkowitz, D. M., Sabounjian, L., Harnett, K., Schwiderski, U., and Gammans, R. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann.Neurol. ;48(5):713-722. View abstract.
Xiong, Y., Liu, X., Wang, Y., and Du, Y. Cloning of cytidine triphosphate: phosphocholine cytidylyltransferase mRNA upregulated by a neuropeptide arginine-vasopressin((4-8)) in rat hippocampus. Neurosci.Lett. 4-7-;283(2):129-132. View abstract.
Yashima, K., Takamatsu, M., and Okuda, K. Intestinal absorption of cytidine diphosphate choline and its changes in the digestive tract. J Nutr Sci Vitaminol.(Tokyo) ;21(1):49-60. View abstract.
Adibhatla RM, Hatcher JF. Citicoline decreases phospholipase A2 stimulation and hydroxyl radical generation in transient cerebral ischemia. J Neurosci Res ;73:308-15. View abstract.
Adibhatla RM, Hatcher JF. Citicoline mechanisms and clinical efficacy in cerebral ischemia. J Neurosci Res ;70:133-9. View abstract.
Aidelbaum R, Labelle A, Baddeley A, Knott V. Assessing the acute effects of CDP-choline on sensory gating in schizophrenia: a pilot study. J Psychopharmacol. ;32(5):541-51. View abstract.
Babb SM, Appelmans KE, Renshaw PF, et al. Differently effect of CDP-choline on brain cytosolic choline levels in younger and older subjects as measured by magnetic resonance spectroscopy. Psychopharmacology (Berl) ;127:88-94. View abstract.
Barrachina M, Dominguez I, Ambrosio S, et al. Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine-treated SH-SY5Y human neuroblastoma cells. J Neurol Sci ;215:105-10. View abstract.
Brown ES, Todd JP, Hu LT, et al. A randomized, double-blind, placebo-controlled trial of citicoline for cocaine dependence in bipolar I disorder. Am J Psychiatry ;172(10):-21. View abstract.
Castagna A, Manzo C, Fabbo A, Lacava R, Ruberto C, Ruotolo G. The CITIMERIVA Study: CITIcoline plus MEmantina plus RIVAstigmine in Older Patients Affected with Alzheimer's Disease. Clin Drug Investig. Feb;41(2):177-182. View abstract.
Cinar E, Yuce B, Aslan F, Erbakan G. Neuroprotective effect of citicoline eye drops on corneal sensitivity after LASIK. J Refract Surg. Dec 1;35(12):764-770. View abstract.
Clark BC, Georgekutty J, Berul CI. Myocardial ischemia secondary to synthetic cannabinoid (K2) use in pediatric patients. J Pediatr ;167(3):757-61.e1. View abstract.
For more information, please visit Difference Between Choline And Citicoline.
Cohen RA, Browndyke JN, Moser DJ, et al. Long-term citicoline (cytidine diphosphate choline) use in patients with vascular dementia: Neuroimaging and neuropsychological outcomes. Cerebrovasc Dis ;16:199-204. View abstract.
Conant R, Schauss AG. Therapeutic applications of citicoline for stroke and cognitive function in the elderly: A review of the literature. Altern Med Rev ;9:17-31. View abstract.
Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin Interv Aging ;8:131-7. View abstract.
Dávalos A, Alvarez-Sabín J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet ;380():349-57. View abstract.
Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: An individual patient date pooling analysis of clinical trials. Stroke ;33:-7. View abstract.
Dempsey RJ, Raghavendra Rao VL. Cytidinediphosphocholine treatment to decrease traumatic brain injury-induced hippocampal neuronal death, cortical contusion volume, and neurological dysfunction in rats. J Neurosurg ;98:867-73. View abstract.
El Sayed I, Zaki A, Fayed AM, Shehata GM, Abdelmonem S. A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. Neurosurg Rev ;41(2):427-38. View abstract.
Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev ;(2):CD. View abstract.
Fogagnolo P, Melardi E, Tranchina L, Rossetti L. Topical citicoline and vitamin B12 versus placebo in the treatment of diabetes-related corneal nerve damage: a randomized double-blind controlled trial. BMC Ophthalmol. Aug 1;20(1):315.View abstract.
Ghajar A, Gholamian F, Tabatabei-Motlagh M, et al. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial. Hum Psychopharmacol. ;33(4):e. View abstract.
Jeong H, Yoon S, Sung YH, et al. Effects of cytidine-5'-diphosphate choline on gray matter volumes in methamphetamine-dependent patients: A randomized, double-blind, placebo-controlled study. J Psychiatr Res ;143:215-221. View abstract.
Licata SC, Penetar DM, Ravichandran C, et al. Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers. J Addict Med ;5(1):57-64. View abstract.
Loebis R, Zulkarnain BS, Siswanto FA. Effectiveness of citicoline in pediatric patients with refractive amblyopia in Surabaya, East Java, Indonesia. J Basic Clin Physiol Pharmacol ;32(4):657-661. View abstract.
Marino PF, Rossi GCM, Campagna G, et al. Effects of citicoline, homotaurine, and vitamin E on contrast sensitivity and visual-related quality of life in patients with primary open-angle glaucoma: A preliminary study. Molecules. Nov 29;25(23):. View abstract.
Martí-Carvajal AJ, Valli C, Martí-Amarista CE, et al. Citicoline for treating people with acute ischemic stroke. Cochrane Database Syst Rev. Aug 29;8:CD. View abstract.
Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Nutr ;151(8):-. View abstract.
Ottobelli L, Manni GL, Centofanti M, et al. Citicoline oral solution in glaucoma: is there a role in slowing disease progression? Ophthalmologica ;229(4):219-26. View abstract.
Parisi V, Centofanti M, Ziccardi L, et al. Treatment with citicoline eye drops enhances retinal function and neural conduction along the visual pathways in open angle glaucoma. Graefes Arch Clin Exp Ophthalmol ;253(8):-40. View abstract.
Parravano M, Scarinci F, Parisi V, et al. Citicoline and vitamin B12 eye drops in type 1 diabetes: Results of a 3-year pilot study evaluating morpho-functional retinal changes. Adv Ther. Apr;37(4):-. View abstract.
Pawar PV, Mumbare SS, Patil MS, Ramakrishnan S. Effectiveness of the addition of citicoline to patching in the treatment of amblyopia around visual maturity: a randomized controlled trial. Indian J Ophthalmol ;62(2):124-9. View abstract.
Rejdak R, Toczolowski J, Krukowski J, et al. Oral citicoline treatment improves visual pathway function in glaucoma. Med Sci Monit ;9:PI24-8. View abstract.
Roohi-Azizi M, Arabzadeh S, Amidfar M, et al. Citicoline combination therapy for major depressive disorder: a randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol ;40(1):1-5. View abstract.
Rossetti L, Iester M, Tranchina L, et al. Can treatment with citicoline eyedrops reduce progression in glaucoma? The results of a randomized placebo-controlled clinical trial. J Glaucoma. Jul;29(7):513-520. View abstract.
Salamah A, Mehrez M, Faheem A, El Amrousy D. Efficacy of Citicoline as a Neuroprotector in children with post cardiac arrest: a randomized controlled clinical trial. Eur J Pediatr. Apr;180(4):-. View abstract.
Savci V, Goktalay G, Cansev M, et al. Intravenously injected citicoline increases blood pressure and reverses hypotension in haemorrhagic shock: effect is mediated by central cholinergic activation. Eur J Pharmacol ;468:129-39. View abstract.
Secades JJ, Alvarez-Sabín J, Castillo J, et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis ;25(8):-96. View abstract.
Shi PY, Zhou XC, Yin XX, Xu LL, Zhang XM, Bai HY. Early application of citicoline in the treatment of acute stroke: a meta-analysis of randomized controlled trials. J Huazhong Univ Sci Technolog Med Sci ;36(2):270-7. View abstract.
Sobrado M, Lopez MG, Carceller F, et al. Combined nipodimine and citicoline reduce infarct size, attenuate apoptosis, and increase BCL-2 expression after focal cerebral ischemia. Neuroscience ;118:107-13. View abstract.
Spiers PA, Myers D, Hochanadel GS, et al. Citicoline improves verbal memory in aging. Arch Neurol ;53:441-8. View abstract.
Teather LA, Wurtman RJ. Dietary cytidine (5)-diphosphocholine supplementation protects against development of memory deficits in aging rats. Prog Neuropsychopharmacol Biol Psychiatry ;27:711'17. View abstract.
Trimmel H, Majdan M, Wodak A, Herzer G, Csomor D, Brazinova A. Citicoline in severe traumatic brain injury: indications for improved outcome: a retrospective matched pair analysis from 14 Austrian trauma centers. Wien Klin Wochenschr. ;130(1-2):37-44. View abstract.
Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci ;56:637-60. View abstract.
Zemel MB, Thompson W, Milstead A, et al. Calcium and dairy acceleration of weight and fat loss during energy restriction in obese adults. Obes Res ;12:582'90. View abstract.
Zweifler RM. Membrane stabilizer: Citicoline. Curr Med Res Opin ;18:s14-s17. View abstract.
In this comprehensive review, we examine the main preclinical and clinical investigations assessing the effects of different forms of choline supplementation currently available, including choline alfoscerate (C8H20NO6P), also known as alpha-glycerophosphocholine (α-GPC, or GPC), choline bitartrate, lecithin, and citicoline, which are cholinergic compounds and precursors of acetylcholine. Extensively used as food supplements, they have been shown to represent an effective strategy for boosting memory and enhancing cognitive function.
Keywords: choline, choline alfoscerate, choline bitartrate, choline supplementation, cognitive dysfunction, GPC, lecithin, supplements
Choline is an important nutrient essential for proper functioning of liver, muscle, and brain (1'5). It is a main constituent of cell and organelle membranes and plays a vital role in numerous physiological processes including signal transduction, DNA and histone methylation, and nerve myelination (6, 7). Choline is a precursor of different metabolites including the neurotransmitter acetylcholine (ACh), the membrane phospholipids phosphatidylcholine (PC) and sphingomyelin, and the methyl donor betaine.
Choline can be obtained from the diet and via de novo biosynthesis from the methylation of phosphatidylethanolamine (PE) to PC (6, 8). The demand for choline increases particularly during pregnancy inasmuch as it is important for placental function, fetal growth, and brain development (7). Choline deficiency can cause serious medical conditions such as premature birth, cystic fibrosis, and hepato-steatosis. Therefore, a sufficient choline intake is necessary for growth and homeostasis.
The US Food and Drug Administration (FDA) identified choline as an essential nutrient in . The National Academy of Medicine (NAM) of the USA and the European Food Safety Authority (EFSA) both specified adequate intake (AI) values for choline. Of course, age, sex, life conditions (pregnancy, breastfeeding), and genetic polymorphisms represent central factors in determining AI (9). In , the European Food Safety Authority (EFSA) set an AI of 400 mg/day for all healthy adults. Similarly, the AIs for pregnant and lactating women are 480 mg/day for and 520 mg/day respectively. The US Institute of Medicine (IOM) has a slightly different choline AIs set for nonpregnant, pregnant, and lactating women: 425 mg/day, 450 mg/day, and 550 mg/day, respectively. Low AIs were set for infants of various ages: AI recommendations for infants 0'6 months are 125 mg choline/day whereas for infants 7'12 months are 150 mg choline/day. These AI values are set according to choline concentrations in human milk (160 mg/L) and estimated average volume of human milk intake (0.78 L/day) for a whole group of infants (aged 0'6 months) with a default body weight of 7 kg (approximately 18 mg/kg), and extrapolation for default body weight (aged 7-12 months) (10, 11). Plasma choline concentrations are three times higher in newborn infants than in their mothers as human milk is rich in choline (12'16).
In addition to choline intake from food, there are several forms of choline supplementation currently available (2). Choline alfoscerate (C8H20NO6P), also known as alpha-glycerophosphocholine (α-GPC, or GPC), is a cholinergic compound and ACh precursor extensively used as a food supplement. Its molecular weight is 257.22 g/mol. GPC is considered one of the most used sources of choline due to its high choline content (41% of choline by weight) and its ability to cross the blood-brain barrier. The content of choline and GPC in common foods is reported in Table 1 .
Choline and GPC content in common foods (mg choline moiety/100 g of food) according to the US Department of Agriculture (USDA); the NDB (Nutrient DataBase) identifier is a five-digit numerical code used by the USDA for standard reference.
NDB No. Description Free Choline GPC Fish, steelhead trout, dried, flesh (Shoshone Bannock) 15.0 190.0 Fish, salmon, red (sockeye), smoked (Alaska Native) 46.0 130.0 Fish salmon, king (chinook), raw (Alaska Native) 20.0 50.0 Fish, salmon, sockeye (red), raw (Alaska Native) 20.0 53.0 Fish, sheefish, dried (Alaska Native) 12.0 74.0 Seal, bearded (oogruk), meat, air-dried (Alaska Native) 17.0 52.0 Fish, salmon, chum, raw (Alaska Native) 23.0 41.0 Fish, salmon, Atlantic, farmed, cooked, dry heat 7.8 41.0 Fish, salmon, Atlantic, farmed, raw 9.9 43.0 Candies, milk chocolate 9.1 22.0 Milk, reduced fat fluid, 2% milk fat, with added vitamin A 2.8 10.0 Yogurt, plain, low fat, 12 g protein per 8 oz 2.3 9.1 Cereals, Quaker, Oat Bran, Quaker/Mother's Oat Bran, dry 4.4 33.0 Candies, milk chocolate pieces, sugar coated 9.6 22 Frozen yogurts, vanilla, fat free 3.7 13.0 Leavening agents, yeast, baker's, active dry 6.1 16.0 Crackers, cheese, sandwich-type with cheese filling 6.7 15.0 Cake, snack cakes, cupcakes, chocolate, with frosting, low- fat 5.0 10.0 Cheese food, pasteurized process, American, without sodium phosphate 7.9 14.0 Candies, milk chocolate coated wafer bars 7.9 16.0 Open in a new tabAfter oral administration, GPC can be readily metabolized to PC, the active form of choline that is able to increase the release of the neurotransmitter ACh (17, 18) and brain-derived neurotrophic factor (BDNF) (19, 20). GPC enhances memory and cognitive function and is well-known to be effective in the treatment of several neurodegenerative and vascular diseases such as Alzheimer's disease and dementia (21'23). GPC has been shown to be more effective when combined with cholinesterase inhibitors (24, 25). Numerous studies have identified the favorable effects of GPC in the treatment of the sequelae of cerebrovascular accidents (26'28).
Nevertheless, GPC can be a friend or a foe depending on the doses and length of its administration. Uncovering a safe therapeutic window is essential to prevent adverse reactions.
GPC has been shown to exhibit a favorable action in experimental models of the aging brain as well as in a rat model of pilocarpine-induced seizure (29, 30), and to promote neuronal differentiation in a rat model of noise-restraint stress (29). In vitro assays performed in the SH-SY5Y human cell line have revealed that this cholinergic compound antagonizes neurotoxicity triggered by the fragment Aβ ( 25'35) of the Alzheimer's amyloid β-peptide and attenuates the Aβ-induced phosphorylation of the Tau protein (31), by sustaining the expression level of synaptic vesicle proteins, such as synaptophysin (32'34). GPC was also shown to increase hippocampal neurogenesis, providing protection against seizure-induced neuronal death and cognitive impairment (26) and to antagonize scopolamine-induced amnesia enhancing hippocampal cholinergic transmission, suggesting that the behavioral effects of GPC could be related to its property to increase hippocampal synthesis and release of ACh (35'38).
Although GPC does not seem to be directly involved in the modulation of inflammatory responses (39), it has been shown to improve mitochondrial function and to reduce oxidative and nitrosative stress (40).
Chronic treatment of aged rats with GPC restored the number of muscarinic M1 receptors to levels found in the striatum and hippocampus from young animals (41). In young but not old rats, GPC significantly potentiated K+-stimulated intra-synaptosomal Ca2+ oscillations in purified synaptosomes derived from the hippocampus (17). Repeated injections of GPC significantly increased basal formation of [3H]inositol monophosphate in hippocampal, cortical, and striatal slices of male rats (42). Consistently, GPC potentiated receptor-stimulated phosphatidylinositol hydrolysis in cortical synapto-neurosomes (17).
In a model of acute cerebral ischemia in rats, GPC increased the tolerance of neurons to ischemic damage and slowed the execution of the cell death program (43). Consistent with these findings, in vitro assays in astroglial cell cultures have shown that GPC increases proliferation (44).
Cholinergic precursors have represented one of the first approaches attempting to relief cognitive impairment in dementia-related disorders. However, controlled clinical trials failed to show significant improvements with choline or PC, choline-containing phospholipids, alone or in association with cholinesterase inhibitors (tacrine plus choline, or physostigmine plus choline) (44, 45). Luckily, the lack of clinical benefits obtained with choline or lecithin are not shared by other phospholipids involved in choline biosynthetic pathways, including GPC and citicoline (cytidine 5'-diphosphocholine, also known as CDP-choline), which are able to increase ACh content and release (44, 46).
A study in male young adults demonstrated that the ingestion of mg GPC significantly increases plasma free choline levels (47). Numerous clinical reports suggest that GPC can improve memory and attention in patients with Alzheimer's disease and dementia (26, 36, 48'54)
GPC advances physical and psychomotor performance in the context of muscle strength and conditioning (55'58). For instance, in a group of 13 college-aged male subjects, the administration of 600 mg GPC resulted in an increase of 98.8 N during an isometric mid-thigh pull assessment (55). Similarly, maximum velocity and maximum mechanical power were improved by the administration of 250 mg GPC (56) and nutritional supplements containing 300 mg or 150 mg GPC were shown to improve reaction time and vertical jump power (59), indicating the ergogenic properties of GPC.
The effects of GPC on cerebrovascular events remain controversial. Indeed, some investigators have conducted a multicenter clinical trial (daily intramuscular dose of mg for 28 days and oral dose of 800 mg during the following 5 months) that revealed the excellent tolerability and the therapeutic role of GPC on cognitive recovery of patients with acute stroke or transient ischemic attack (TIA) (18); on the other hand, a recent retrospective study has shown that GPC is associated with a higher 10-year incident stroke risk in a dose-response manner after adjusting for traditional cerebrovascular risk factors (60). A potential explanation for these different findings could be the diverse effects of GPC supplementation on the gut microbial community structure: in this sense, a recent preclinical report demonstrated that GPC can cause a shift in the murine microbiota, characterized by increased abundance of Bacteroides, Parabacteroides, and Ruminococcus, and decreased abundance of Lactobacillus, Akkermansia, and Roseburia (61).
Most recently, in a prospective study, GPC was suggested to enrich listening comprehension in older adults using hearing aids (62). Due to its action on the parasympathetic nervous system, GPC has also shown beneficial effects in patients with dry eye (keratoconjunctivitis sicca) and its combination with D-Panthenol accelerated and modulated the repair of the corneal innervation after cataract surgery (63'66).
In addition to GPC, other supplements are available to ensure an adequate intake of choline ( Table 2 ). One of the most used is choline bitartrate, which has shown favorable effects both in preclinical and clinical studies, especially in terms of improved cognitive function (67'73).
Characteristics of the main different forms of choline supplementation.
GPC Choline bitartrate Lecithin Citicoline IUPAC Name [(2R)-2,3-dihydroxypropyl] 2-(trimethylazaniumyl)-ethyl phosphate (2-hydroxyethyl)-trimethylazanium (2R,3R)-3-carboxy-2,3-dihydroxypropanoate [(2R)-3-hexadecanoyloxy-2-[(9E,12E)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)-ethyl-phosphate [[(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] 2-(trimethylazaniumyl)-ethyl phosphate Molecular Formula C8H20NO6P C9H19NO7 C42H80NO8P C14H26N4O11P2 Molecular Weight (g/mol) 257.22 253.25 758.075 488.32 Color/Form Solid White crystalline powder Yellow-brownish powder White crystalline powder Odor Odorless Odorless or faint trimethylamine-like odor Odorless or has nut-like smell High doses can cause fishy odor Taste No taste Acidic taste Nutty taste Neutral Melting Point 142.5°C 149-153°C 236.1°C 240-242°C Solubility Very soluble in water Freely soluble in water; slightly soluble in alcohol; insoluble in ether, chloroform, and benzene Low solubility in water, but serves as an excellent emulsifier Very soluble in water Open in a new tabImportantly, a prospective randomized cross-over study was designed to compare four different choline supplements in terms of their impact on plasma concentration and kinetics of choline; participants received a single dose of 550 mg/d choline equivalent in the form of choline chloride, GPC, egg-PC, and choline bitartrate, in randomized sequence at least 1 week apart; the analysis of these revealed no difference in the area-under-curve of choline plasma concentrations after intake of the different supplements (74).
The main clinical trials assessing the effects of choline supplementation, in different formulations, are reported in Table 3 .
Main clinical studies investigating choline supplementation.
Trial Supplementation Subjects Results Ref. Randomized cross-over study (DRKS) choline chloride, choline bitartrate, GPC, egg-PC 6 healthy adult men -All supplements promptly raised choline and betaine levels to a similar extent, with egg-PC showing the latest peak. Considering TMAO may have unfavorable effects, egg-PC might be the best choline supplementation in adults. (74) Randomized double-blind placebo-controlled parallel clinical trialCholine bitartrate (C9H19NO7) is a white crystalline powder with no odor. Its molecular weight is 253.25 g/mol with 41.1% choline (104 g/mol choline in 253.25 g/mol choline bitartrate); 2'g of choline bitartrate administration provides 800'mg of choline action (70). It is freely soluble in water, slightly soluble in alcohol and insoluble in ether, chloroform, and benzene.
Choline bitartrate is widely used in dietary supplements. One of the main advantage of bitartrate is its lower hygroscopicity (89), a feature that in the last years has triggered an increase of its use. The methyl donor betaine, a choline derivative, has been shown to facilitate the cytosolic re-methylation of homocysteine to methionine in a reaction catalyzed by the enzyme betaine-homocysteine S-methyltransferase (BHMT). The same reaction is also catalyzed by the methionine synthase, which uses methyl-cobalamin as a co-factor and is a vitamin B12 dependent enzyme (82, 90). Preclinical studies have reported a choline-sparing effect of vitamin B12 supplementation (91'93) and patients deficient in vitamin B12 have lower blood concentrations of choline (94). These aspects provide a strong rationale for the preparation of formulations in which choline, especially choline bitartrate, is associated with vitamin B12.
Lecithin is a mixture of fats and can be obtained from food such as egg yolks (actually, the term lecithin derives from the Greek word λέκιθος, lekythos, which means 'egg yolk'), soybeans, and nuts (95, 96). PC represents one of the main components of lecithin, albeit the two terms are sometimes used interchangeably. Lecithin is essential to cells in the human body. Since lecithin is converted into ACh, its consumption increases ACh concentrations in the brain (97). Several studies have been carried out showing the effects of consumption of lecithin on hypercholesterolemia and cardiovascular disorders (98, 99).
Citicoline is a brain chemical that occurs naturally in the cells, especially organs, of human and animals. It is a natural precursor of phospholipid synthesis, chiefly PC, and serves as a source of choline in the metabolic pathways for biosynthesis of ACh in the body (100). Citicoline enhances cerebral metabolism and has neuroprotective properties in animals and humans (101'103). Citicoline is effective in facilitating cognitive improvement in various conditions, including vascular and degenerative dementias, cerebrovascular diseases, amyotrophic lateral sclerosis, Alzheimer's disease, and also Parkinson's disease (104, 105); indeed, citicoline increases brain dopamine levels and may inhibit dopamine reuptake (104).
Endothelial cells play a crucial role in the exchange of choline and other nutrients between plasma and brain tissue (75, 106'108). Thus, choline must be incorporated into endothelial cells to be transported to the blood-brain barrier (109). Choline supplementation was shown to be effective against hypoxia-induced endothelial dysfunction by Zhang and co-workers, who demonstrated that choline enhanced rat aortic endothelial cell proliferation during hypoxia by secreting vascular endothelial growth factor (VEGF) (6). Moreover, choline supplementation activated the α7 non-neuronal nicotinic ACh receptors (nAChRs) and served as a key function in regulating blood vessels. Thus, choline can be protective against hypoxia-induced endothelial dysfunction (6, 110). Although the benefits of choline have been reported, the exact mechanisms in protecting endothelial function are yet to be fully defined.
Some investigators have reported that endothelial dysfunction is linked with various cardiovascular diseases (111, 112). Several studies have demonstrated the role of high choline intake and its metabolite trimethylamine N'oxide (TMAO) in endothelial dysfunction and atherosclerosis (111, 113'117). Instead, phloretin, a flavonoid extracted from apple leaves, plays a protective role, and improves vascular endothelial dysfunction and liver injury (111).
Models of endothelial dysfunction like hypoxia or oxygen and glucose deprivation (OGD) were used to evaluate the effects of citicoline on human umbilical vein endothelial cells (HUVECs) and mouse brain microvascular endothelial cells (bEnd.3s) (105, 118'120). Citicoline attenuated the hypoxia/OGD-induced increase in endothelial permeability via upregulating the expression of tight junction proteins including zonula occludens-1, occludin, and claudin-5. Thus, citicoline could be an efficient therapeutic drug for targeting diseases characterized by endothelial barrier breakdown (105).
Choline plays a protective role in the heart and may be a promising candidate to improve doxorubicin-induced cardiotoxicity via vagal activity and Nrf2/HO-1 pathway (121). Moreover, choline exhibits protective effects against cardiovascular disorders, including arrhythmias, cardiac hypertrophy, and ischemia/reperfusion (I/R)-induced vascular injury by inhibiting the ROS-mediated Ca2+/calmodulin-dependent protein kinase II pathway (122'124). Citicoline acts as a myocardial protector from I/R injury via inhibiting mitochondrial permeability transition (125). Choline was also shown to ameliorate cardiovascular damage by slowing the progression of hypertension and enhancing cardiac function in spontaneously hypertensive rats (126).
Low amounts of choline can reduce cardiovascular risks and inflammatory markers as they have lowering effect on plasma homocysteine (127). In contrast, a choline' or carnitine'rich diet was reported to promote atherosclerosis in mice as it increased the formation of TMAO produced by gut microbiota-related metabolite of choline (128). Similarly, other papers have reported the association of TMAO with an increased risk of cardiovascular disease and mortality (60, 113, 129'131). Dietary lecithin has shown favorable results with potential application in the treatment of dyslipidemia associated with metabolic disorders (132). Obesity is linked with several cardio-metabolic chronic diseases, such as non-alcoholic fatty acid liver disease (NAFLD), type-2 diabetes, and cardiovascular disease. Numerous studies have also investigated the beneficial effects of lecithin on obesity-related dyslipidemia (132'135). Lecithin-rich diets have hypocholesterolemic effects and display anti-atherogenic properties (136).
Intake of choline and betaine co-supplementation was not associated to cancer or cardiovascular disease; however, an adverse cardiovascular risk factor profile was linked with high choline and low betaine levels in plasma. Therefore, choline and betaine demonstrated opposite relationships with major components of metabolic syndrome (92). Choline and betaine supplementation has not been extensively studied in clinical trials for treating obesity and maintaining normal systemic metabolism. Notwithstanding, Sivanesan and co-workers revealed that choline and betaine administration is favorable for obese and insulin resistant Pcyt2+/- mice; they suggested that choline and betaine supplementations could be beneficial for the treatment of obesity and diabetes due to their participation in mitochondrial oxidative phosphorylation (137).
Environmental factors may contribute to the pathological progression of neurodegenerative diseases and epilepsy. Remarkably, dietary nutrients play an important part in facilitating mechanisms related to brain function (138). As mentioned above, ACh receptors orchestrate the immune response in the central nervous system, and their dysregulation plays a part in the pathogenesis of Alzheimer's disease (139'144). In fact, Velasquez and collaborators demonstrated that a lifelong choline supplementation may have beneficial cognitive effects such as decreasing amyloid-β plaque load and improving spatial memory in the APP/PS1 mouse model of Alzheimer's disease. Moreover, consumption of healthy diet throughout life may reduce Alzheimer's disease pathology (139). In another paper, the same group reported that maternal choline supplementation has profound benefits in Alzheimer's disease pathology by reducing brain homocysteine levels across multiple generations (145). Several studies have been carried out to investigate the impact of choline supplementation on cognitive functioning in the Ts65Dn mouse model of Down syndrome; for instance, perinatal choline supplementation was reported to enhance emotion regulation in Down syndrome (146). Other studies revealed that maternal choline supplementation improves spatial learning, increases adult hippocampal neurogenesis and basal forebrain cholinergic neurons (147, 148). Bottom and colleagues demonstrated that co-supplementation of choline protects against effects of prenatal ethanol exposure in fetal alcohol spectrum disorder (FASD) offspring (149). Increasing the intake of choline may also reduce spatial memory deficits due to the exposure of chemotherapeutic agents such as cyclophosphamide and doxorubicin in cancer patients (150).
Several researchers have tested the effects of high uptake of dietary choline in elderly patients suffering from impaired memory. A cross-sectional study conducted on ~ elderly patients demonstrated that choline intake, defined as the combination of dietary and supplement intake, correlates with cognitive performance (151). Choline supplements in the form of lecithin and choline chloride did not significantly improve memory performance in humans although some papers have reported positive outcomes in cognitive function of animal models (152'156). However, other choline supplements such as citicoline, choline bitartrate, and GPC appear to be very promising in the treatment of elderly patients suffering from dementia (49, 52, 54, 157, 158).
In summary, preclinical and clinical investigations have shown that GPC and other forms of choline supplementation have beneficial effects especially in terms of improved endothelial function and cognitive performance. Notwithstanding, further dedicated studies are warranted to compare the different effects of the currently available forms of choline supplementation.
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
The authors thank Dr. Wang for the valuable support.
The Santulli's Lab is supported in part by the National Institutes of Health (NIH): National Heart, Lung, and Blood Institute (NHLBI: R01-HL, R01-HL, R01-HL, T32-HL), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK: R01-DK, R01-DK), National Center for Advancing Translational Sciences (NCATS: UL1TR-06) to G.S., by the Diabetes Action Research and Education Foundation (to G.S.), and by the Monique Weill-Caulier and Irma T. Hirschl Trusts (to G.S.). U.K. is supported in part by a postdoctoral fellowship of the American Heart Association (AHA-23POST). F.V. is supported in part by a postdoctoral fellowship of the American Heart Association (AHA-22POST).
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
For more How Much Citicoline Should I Takeinformation, please contact us. We will provide professional answers.